NDAINTRAVENOUSPOWDERPriority Review
Approved
Feb 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
7/8 — Comprehensive
Priority Review
AVYCAZ (ceftazidime, avibactam) by AbbVie is [ see clinical pharmacology ( ) ]. Approved for the following infections caused by designated susceptible gram-negative microorganisms in adult, used in combination with metronidazole ( ) complicated urinary tract infections (cuti), including pyelonephritis ( ) hospital-acquired bacterial pneumonia and 19 more indications. First approved in 2015.
Drug data last refreshed 11h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AVYCAZ is a fixed-dose combination of ceftazidime (a third-generation cephalosporin) and avibactam (a beta-lactamase inhibitor) administered intravenously to treat serious Gram-negative bacterial infections. It works by enhancing cephalosporin activity against resistant organisms by blocking bacterial beta-lactamase enzymes. The drug is indicated for complicated urinary tract infections, hospital-acquired/ventilator-associated pneumonia, and complicated intra-abdominal infections in adults.
$16MPart D
PeakStable
5.9 years to LOEProduct is at peak commercial maturity with modest Part D volume; brand teams will focus on maintaining market share against emerging resistance-focused competitors rather than growth acceleration.
Mechanism of Action
[ see Clinical Pharmacology ( ) ].
Worked on AVYCAZ at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.